8156 — Sinopharm Tech Holdings Income Statement
0.000.00%
Last trade - 00:00- HK$205.95m
- HK$344.60m
- HK$61.25m
- 15
- 21
- 79
- 28
Annual income statement for Sinopharm Tech Holdings, fiscal year end - June 30th, HKD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | R2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 77.8 | 41 | 42.8 | 41.3 | 61.3 |
| Cost of Revenue | |||||
| Gross Profit | 20.9 | 5.93 | 5.47 | 5.02 | 14.2 |
| Selling / General / Administrative Expenses | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 178 | 119 | 45.3 | 37.7 | 56.5 |
| Operating Profit | -100 | -77.6 | -2.46 | 3.6 | 4.78 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -111 | -94.2 | -10.8 | -20.3 | -1.08 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -111 | -93.8 | -9.54 | -20.4 | -1.37 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -106 | -88 | -10.6 | -19.7 | -0.867 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -106 | -88 | -10.6 | -19.7 | -0.867 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.458 | -0.442 | -0.028 | -0.168 | -0.017 |